Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Pancreatic Ductal
  • Chemoradiotherapy, Adjuvant
  • Pancreatic Neoplasms
  • Quinazolines

abstract

  • Erlotinib can be safely administered with adjuvant IMRT-based CRT and chemotherapy. The efficacy of this regimen appears comparable to that of existing adjuvant regimens. Radiation Therapy Oncology Group 0848 will ultimately determine whether erlotinib produces a survival benefit in patients with resected pancreatic cancer.

publication date

  • July 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4322929

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2013.03.032

PubMed ID

  • 23773391

Additional Document Info

start page

  • 678

end page

  • 85

volume

  • 86

number

  • 4